These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37724000)

  • 1. Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of the Congo.
    Mitangala PN; Irenge LM; Musubao ET; Kahindo JBM; Ayonga PN; Kyembwa Safari I; Kubuya JB; Ntabe EN; Kabangwa Senga RK; Mutombo GN; Ambroise J; Gala JL
    Epidemiol Infect; 2023 Sep; 151():e167. PubMed ID: 37724000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of COVID-19 infection in a densely populated district in the eastern Democratic Republic of Congo.
    Irenge LM; Bulakali HM; Akonkwa AI; Ambroise J; Gala JL
    Epidemiol Infect; 2023 Feb; 151():e24. PubMed ID: 36775822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Seroprevalence of SARS-CoV-2 antibodies among travellers and workers screened at the Saint Luc Clinic in Bukavu, a city in eastern Democratic Republic of the Congo, from May to August 2020].
    Katchunga PB; Murhula A; Akilimali P; Zaluka JC; Karhikalembu R; Makombo M; Bisimwa J; Mubalama E
    Pan Afr Med J; 2021; 38():93. PubMed ID: 33889259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Prevalence of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (Anti-SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey.
    Nkuba AN; Makiala SM; Guichet E; Tshiminyi PM; Bazitama YM; Yambayamba MK; Kazenza BM; Kabeya TM; Matungulu EB; Baketana LK; Mitongo NM; Thaurignac G; Leendertz FH; Vanlerberghe V; Pelloquin R; Etard JF; Maman D; Mbala PK; Ayouba A; Peeters M; Muyembe JT; Delaporte E; Ahuka SM
    Clin Infect Dis; 2022 Mar; 74(5):882-890. PubMed ID: 34089598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High SARS-CoV-2 Seroprevalence in Healthcare Workers in Bukavu, Eastern Democratic Republic of Congo.
    Mukwege D; Byabene AK; Akonkwa EM; Dahma H; Dauby N; Cikwanine Buhendwa JP; Le Coadou A; Montesinos I; Bruyneel M; Cadière GB; Vandenberg O; Van Laethem Y
    Am J Trop Med Hyg; 2021 Feb; 104(4):1526-1530. PubMed ID: 33591936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of anti-SARS-CoV-2 antibodies and risk of viral exposure among healthcare workers in the South Kivu province, eastern Democratic Republic of the Congo: a cross-sectional study.
    Chasinga TB; Cikwanine JB; Kribi S; Yoyu JT; Hofmann N; Grossegesse M; Nitsche A; Tomczyk S; Vietor AC; Leendertz FH; Eckmanns T; Kusinza AB; Munguakonkwa E; Kalk A; Raha M; Kambale NS; Ayagirwe RB; Schubert G; Mukwege D
    BMJ Open; 2024 Jan; 14(1):e072212. PubMed ID: 38176860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.
    Munyeku-Bazitama Y; Folefack GT; Yambayamba MK; Tshiminyi PM; Kazenza BM; Otshudiema JO; Guinko NT; Umba MD; Mulumba A; Baketana LK; Mukadi PK; Smith C; Muyembe-Tamfum JJ; Ahuka-Mundeke S; Makiala-Mandanda S
    Emerg Infect Dis; 2023 Jan; 29(1):89-97. PubMed ID: 36573545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali.
    Laverdure S; Kazadi D; Kone K; Callier V; Dabitao D; Dennis D; Haidara MC; Hunsberger S; Mbaya OT; Ridzon R; Sereti I; Shaw-Saliba K;
    Int J Infect Dis; 2024 May; 142():106985. PubMed ID: 38417612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study.
    Lawal BJ; Gallagher KE; Kitonsa J; Tindanbil D; Kasonia K; Drammeh A; Lowe B; Mukadi-Bamuleka D; Patterson C; Greenwood B; Samai M; Leigh B; Tetteh KKA; Ruzagira E; Watson-Jones D; Kavunga-Membo H
    Int J Infect Dis; 2023 Jun; 131():183-192. PubMed ID: 37001799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-CoV-2 antibodies in Republic of Congo, February 2022.
    Ndziessi G; Niama RF; Aloumba AG; Peya JM; Ngatse JA; Ngoyomi RA; Niama AC; Tobi N; Loussambou A; Kankou JM; Atipo B; Emeka JC; Ibata P; Moukassa D; Dokekias AE
    Epidemiol Infect; 2023 Sep; 151():e162. PubMed ID: 37800463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.
    Raqib R; Sarker P; Akhtar E; Nurul Huda TM; Haq MA; Roy AK; Hosen MB; Haque F; Chowdhury MR; Reidpath DD; Emdadul Hoque DM; Islam Z; Ahmed S; Ahmed T; Tofail F; Razzaque A
    PLoS One; 2022; 17(5):e0268093. PubMed ID: 35604947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Pandemic: Knowledge and Attitudes in Public Markets in the Former Katanga Province of the Democratic Republic of Congo.
    Carsi Kuhangana T; Kamanda Mbayo C; Pyana Kitenge J; Kazadi Ngoy A; Muta Musambo T; Musa Obadia P; Katoto PDMC; Banza Lubaba Nkulu C; Nemery B
    Int J Environ Res Public Health; 2020 Oct; 17(20):. PubMed ID: 33066059
    [No Abstract]   [Full Text] [Related]  

  • 15. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample.
    Han J; Baek HJ; Noh E; Yoon K; Kim JA; Ryu S; Lee KO; Park NY; Jung E; Kim S; Lee H; Hwang YS; Jung J; Lee HJ; Cho SI; Oh S; Kim M; Oh CM; Yu B; Hong YS; Kim K; Jung SJ; Han MA; Lee MS; Lee JJ; Hwangbo Y; Yim HW; Kim YM; Lee J; Lee WY; Park JH; Oh S; Jo HS; Kim H; Kang G; Nam HS; Lee JH; Oh GJ; Shin MH; Ryu S; Hwang TY; Park SW; Kim SK; Seol R; Park KS; Kim SY; Kwon JW; Kim SS; Kim B; Lee JW; Jang EY; Kim AR; Nam J; ; Lee SY; Kim DH
    Epidemiol Health; 2023; 45():e2023075. PubMed ID: 37591786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Newborn Dried Blood Spots to Ascertain Seroprevalence of SARS-CoV-2 Antibodies Among Individuals Giving Birth in New York State, November 2019 to November 2021.
    Damjanovic A; Styer LM; Nemeth K; Yauney E; Rock JM; Bievenue R; Hoen R; Ehrbar D; Kay DM; Caggana M; Parker MM
    JAMA Netw Open; 2022 Aug; 5(8):e2227995. PubMed ID: 35994287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.